Pharmacokinetics and relative bioavailability of clarithromycin capsule

岗艳云,路丽芳,伍斌,高立勤,尹鸿萍,刘毓文,朱成举
2000-01-01
Abstract:OBJECTIVE: To study the pharmacokinetics and relative bioavailability of clarithromycin capsule: METHODS: A microbiological agar diffusion assay using Micrococcus luteus (ATCC 28001) was used as a bioassay for clarithromycin in serum following a single oral dose 500 mg of clarithromycin capsule and tablet respectively given to 10 healthy volunteers in an open randomized crossover test. The data obtained were fitted with PKBP-N1 program. RESULTS:A linear relationship was obtained between the peak area ratio and the concentration of clarithromycin from 0.05 to 4.00 μg.ml -1 and the lowest limit of detection of clarithromycin in serum was 0.05 μg.ml -1. Precisions were under 8.20%. The recoveries were 99.04% ~ 101.48%. The one-compartment open model with first order absorption was used to described the time course of serum concentrations of clarithromycin in human following administration of a single oral dose 500 mg as capsule and tablet. The results were t(peak) = (1.45 ± 0.50) h and (1.55 ± 0.44) h, c(max) = (2.20 ± 0.39) μg.ml -1 and (2.15 ± 0.33) μg.ml -1, AUC = (17. 60 ± 2.85) μg.h ml -1 and (17.74 ± 3. 46) μg.h.ml -1. CONCLUSION: There were no significant differences between their pharmacokinetic parameters. The tested capsule and the reference tablet is bioequivalent with F(rel) = 101.64%.
What problem does this paper attempt to address?